Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

The NFL confirmed this week that Peyton and Eli Manning will coach the AFC and NFC rosters at the 2025 Pro Bowl Games in Orlando, Florida. This year’s games will mark the third straight year ...

While Eli Lilly missed on both the top and bottom lines in its Q3 financial results, a look at its sales figures -- and especially sales growth -- would make many other pharmaceutical companies ...

Eli Lilly's business is growing fast, but it wasn't enough for analysts and investors. It also slashed its earnings guidance for the year. The stock has been trading at a high valuation, and that ...

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Former New York Giants quarterback Eli Manning headlines six first-year eligible candidates voted as semifinalists for election into the Pro Football Hall of Fame's class of 2025, as announced on ...

Despite the recent damages suffered during Hurricane Helene, this year appears to be no different with Sports Business Journal reporting that New York Giants legend Eli Manning will headline this ...

Eli Lilly (LLY) missed Wall Street's revenue expectations in its third quarter earnings released Wednesday morning, which sent shares down more than 6%. The drugmaker also slashed its profit ...